EU Clinical Trial Regulation: Overview and Implementation (London, United Kingdom - October 19-20, 2020) - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "EU Clinical Trial Regulation: Overview and Implementation" conference has been added to ResearchAndMarkets.com's offering.

This course will provide an essential understanding to help with compliance with the new regulation and associated implementing acts and other texts for carrying out clinical trials in the EU

The new EU Clinical Trial Regulation (536/2014) will replace the European Clinical Trials Directive (2001/20/EC). Key aims of the new Regulation are to harmonise procedures for carrying out clinical trials across the EU and to simplify the clinical trial approval dossier by submission through a new clinical trial database and portal. Once the electronic portal and database are fully functional and the European Commission has given its approval, it will take six months to become applicable. Guidelines for enacting the new Regulation have also been prepared in a number of areas including inspection, investigational medicinal products and trial documentation.

This course will provide an essential understanding to help with compliance with the new Regulation and associated implementing acts and other texts for carrying out clinical trials in the EU. The programme will highlight the most important of these key requirements and changes and how these are likely to impact on trials for biopharmaceutical companies, CROs and study sites.

Benefits of attending:

• Gain an overview of the Clinical Trial Regulation and changes for trials in the EU
• Review how the new Regulation differs from the previous Clinical Trials Directive
• Discuss the Clinical Trial Regulation delegated acts and other implementation documents
• Understand the new EU clinical trial authorisation process, including considerations for the UK

Key topics to be covered include:

• Implications of having a regulation instead of a directive
• Clinical trial transparency
• Clinical trial authorisation process
• Co-sponsorship
• Safety reporting
• Trials with authorised medicinal products
• Risk-based considerations
• Non-EU sponsors
• Requirements for managing investigational medicinal products
• Clinical trials conducted on children
• Regulatory inspection

Agenda:

Background to the EU Clinical Trial Regulation (536/2014)

• The development of European clinical trial legislation
• The framework of clinical trial regulations in Europe
• Overview of the current Clinical Trials Directive requirements
• Problems with the Clinical Trials Directive
• Directive vs Regulation - what are the main differences?

Changes in the new EU Clinical Trial Regulation

• Overview of the major new requirements of the Regulation including:
• Risk-based evaluations
• Non-EU sponsors
• Transparency
• Informed consent
• Co-sponsorship

EU Clinical Trial Regulation documents

• Serious breaches
• Risk-proportionate approaches in clinical trials
• Summaries of clinical trial results for laypersons
• ICH GCP (R2)
• New requirements for the trial master file
• Q&A document

Clinical trial regulatory authorisation and ethical approval

• The significant changes in clinical trial approval in the EU
• The new clinical trial authorisation process
• Substantial modifications

Investigational medicinal product/auxiliary product guidelines

• GMP requirements
• Key requirements for IMPs and AMPs (auxiliary medicinal products)
• Requirements for labelling and packaging

Pharmacovigilance and adverse event reporting

• Adverse event reporting - requirements and definitions
• Safety reporting requirements
• RSI (reference safety information)

Considerations for clinical trials conducted with minors

• EU guidance for running clinical trials on children
• Assent and consent
• Key differences and requirements for running clinical trials on children compared to adults

Considerations for regulatory inspection

• GCP and GMP inspection guidelines
• How to prepare for inspection under the new EU clinical trial requirements

Speakers:

Laura Brown
Pharmaceutical QA and Training Consultant
University of Cardiff

Dr Laura Brown MBA, BSc, PhD, is a Pharmaceutical QA and Training Consultant, Course Director for the MSc in Clinical Research, School of Pharmacy at the University of Cardiff. She has more than 20 years' experience of quality assurance in the pharmaceutical industry and has worked for several companies, including GSKs Hoechst Marion Roussel, Farmitalia and Phoenix International. She has a particular expertise in quality assurance including risked based approaches to quality systems, data Integrity and project management in the pharmaceutical industry. She regularly writes on pharmaceutical regulatory issues including The Planning of International Drug Development, in the Clinical Research Manual, Euromed and the Impact of Brexit, RQA Journal 2017.

For more information about this conference visit https://www.researchandmarkets.com/r/gad1l4